生物标志物在新生血管性年龄相关性黄斑变性中的未来:活动性疾病还是退行性过程?

IF 0.9 Q4 OPHTHALMOLOGY

Expert Review of Ophthalmology Pub Date : 2022-09-03 DOI:10.1080/17469899.2022.2139677

Daniel Egger, Reinhard Angermann, S. Waldstein

{"title":"生物标志物在新生血管性年龄相关性黄斑变性中的未来:活动性疾病还是退行性过程?","authors":"Daniel Egger, Reinhard Angermann, S. Waldstein","doi":"10.1080/17469899.2022.2139677","DOIUrl":null,"url":null,"abstract":"The introduction of intravitreal injections of anti-vascular endothelial growth factor (VEGF) has led to a new standard of care regarding the treatment of neovascular age-related macular degeneration (nAMD). Although VEGF inhibitors caused a paradigm shift in the management of these patients, the burden of frequent follow-up and direct as well as indirect costs of treatment remain a challenge for patients, healthcare systems, and societies. Initial treatment and particularly retreatment decisions still rest upon optical coherence tomography (OCT)-based biomarkers, especially the presence of subretinal fluid (SRF) and intraretinal fluid (IRF). A complete resolution of fluid is often considered a therapeutic target. However, in order to further reduce disease burden and adapt treatment frequency to the individual disease activity, this paradigm needs to be reconsidered.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"17 1","pages":"303 - 306"},"PeriodicalIF":0.9000,"publicationDate":"2022-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The future of biomarkers in neovascular age-related macular degeneration: active disease or degenerative process?\",\"authors\":\"Daniel Egger, Reinhard Angermann, S. Waldstein\",\"doi\":\"10.1080/17469899.2022.2139677\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The introduction of intravitreal injections of anti-vascular endothelial growth factor (VEGF) has led to a new standard of care regarding the treatment of neovascular age-related macular degeneration (nAMD). Although VEGF inhibitors caused a paradigm shift in the management of these patients, the burden of frequent follow-up and direct as well as indirect costs of treatment remain a challenge for patients, healthcare systems, and societies. Initial treatment and particularly retreatment decisions still rest upon optical coherence tomography (OCT)-based biomarkers, especially the presence of subretinal fluid (SRF) and intraretinal fluid (IRF). A complete resolution of fluid is often considered a therapeutic target. However, in order to further reduce disease burden and adapt treatment frequency to the individual disease activity, this paradigm needs to be reconsidered.\",\"PeriodicalId\":39989,\"journal\":{\"name\":\"Expert Review of Ophthalmology\",\"volume\":\"17 1\",\"pages\":\"303 - 306\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2022-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17469899.2022.2139677\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17469899.2022.2139677","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 1

摘要

玻璃体内注射抗血管内皮生长因子（VEGF）的引入为治疗新生血管性年龄相关性黄斑变性（nAMD）带来了新的护理标准。尽管VEGF抑制剂导致了这些患者管理模式的转变，但频繁随访的负担以及直接和间接的治疗成本仍然是患者、医疗系统和社会面临的挑战。初始治疗，尤其是再治疗的决定仍然取决于基于光学相干断层扫描（OCT）的生物标志物，尤其是视网膜下液（SRF）和视网膜内液（IRF）的存在。液体的完全溶解通常被认为是治疗目标。然而，为了进一步减轻疾病负担并使治疗频率适应个体疾病活动，需要重新考虑这种模式。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The future of biomarkers in neovascular age-related macular degeneration: active disease or degenerative process?

The introduction of intravitreal injections of anti-vascular endothelial growth factor (VEGF) has led to a new standard of care regarding the treatment of neovascular age-related macular degeneration (nAMD). Although VEGF inhibitors caused a paradigm shift in the management of these patients, the burden of frequent follow-up and direct as well as indirect costs of treatment remain a challenge for patients, healthcare systems, and societies. Initial treatment and particularly retreatment decisions still rest upon optical coherence tomography (OCT)-based biomarkers, especially the presence of subretinal fluid (SRF) and intraretinal fluid (IRF). A complete resolution of fluid is often considered a therapeutic target. However, in order to further reduce disease burden and adapt treatment frequency to the individual disease activity, this paradigm needs to be reconsidered.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Ophthalmology Health Professions-Optometry

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The worldwide problem of visual impairment is set to increase, as we are seeing increased longevity in developed countries. This will produce a crisis in vision care unless concerted action is taken. The substantial value that ophthalmic interventions confer to patients with eye diseases has led to intense research efforts in this area in recent years, with corresponding improvements in treatment, ophthalmic instrumentation and surgical techniques. As a result, the future for ophthalmology holds great promise as further exciting and innovative developments unfold.